<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296022</url>
  </required_header>
  <id_info>
    <org_study_id>NL34725.018.10</org_study_id>
    <secondary_id>NL34725.018.10</secondary_id>
    <nct_id>NCT01296022</nct_id>
  </id_info>
  <brief_title>A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy</brief_title>
  <acronym>PRAETORIAN</acronym>
  <official_title>Randomized Trial to Study the Efficacy and Adverse Effects of the Subcutaneous and Transvenous Implantable Cardioverter Defibrillator (ICD) in Patients With a Class I or IIa Indication for ICD Without an Indication for Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will outline the advantages and disadvantages of the
      subcutaneous implantable cardioverter defibrillator (ICD) compared to the transvenous ICD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study: The use of implantable cardioverter defibrillators (ICDs) is an
      established therapy for the prevention of death from ventricular arrhythmia. Recently a new
      subcutaneous ICD has been introduced, eliminating the need for transvenous lead placement in
      or on the heart which is mandatory in the transvenous ICD. The new subcutaneous ICD therapy
      already proved to be feasible and safe and is an approved therapy in Europe. It is likely
      that the eliminated need for transvenous lead placement substantially reduces the
      implantation related complications and elongates lead longevity and thus reduces
      inappropriate shocks associated with lead fractures. On the other hand it is unclear whether
      the lack of capability to provide antitachy-pacing (ATP) in the subcutaneous ICD may be a
      limitation for patients with frequent recurrent ventricular tachycardia. This randomized
      controlled trial will outline the advantages and disadvantages of the subcutaneous ICD.

      Objectives of the study: (1) To compare the subcutaneous ICD to the transvenous ICD for major
      adverse events (i.e. inappropriate shocks, acute and chronic implant related complications
      and lead- or device related complications). (2) To determine to which degree the lack of ATP
      function leads to more appropriate shocks in patients with a subcutaneous ICD.

      Study design: Multicenter, prospective, randomized controlled trial with either treatment
      with the transvenous ICD or subcutaneous ICD (1:1).

      Study population: 2x425 patients with class I or IIa indication for ICD therapy without an
      indication for pacing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with implantable cardioverter defibrillator (ICD) related adverse events</measure>
    <time_frame>48 months</time_frame>
    <description>ICD related adverse events are defined as inappropriate shocks and/or implant-, lead- and device related complications. An inappropriate shock is shock therapy for anything else but ventricular fibrillation or ventricular tachycardia. Implant related complications are defined as ICD related infections, ICD related bleedings, thrombotic events, need for lead reposition, post-implant pneumothorax, post-implant hematothorax, or post-implant perforation/tamponade. Lead- or device related complications are all complications related to the lead or device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>48 months</time_frame>
    <description>MACE is defined as cardiac death, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting and/or any valve surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of appropriate shocks</measure>
    <time_frame>48 months</time_frame>
    <description>An appropriate shock is shock therapy for ventricular fibrillation or ventricular tachycardia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of inappropriate shocks</measure>
    <time_frame>48 months</time_frame>
    <description>Inappropriate shocks are defined as above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of complications individually</measure>
    <time_frame>48 months</time_frame>
    <description>Complications are defined as above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 months</time_frame>
    <description>The quality of life is measured by the SF-36 and Duke Activity Status Index questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to successful therapy</measure>
    <time_frame>48 months</time_frame>
    <description>Time to successful therapy is the time between the start of VT or VF until the first successful shock or first successful ATP episode. This includes the time of sensing and charging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First shock conversion efficacy</measure>
    <time_frame>48 months</time_frame>
    <description>First shock conversion efficacy is the amount of patients with VT or VF who are successfully converted with the first shock given by the transvenous ICD or subcutaneous ICD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant procedure time</measure>
    <time_frame>48 months</time_frame>
    <description>Implant procedure time is the time between the first incision and placement of the last suture (skin-to-skin time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>48 months</time_frame>
    <description>The hospitalization rate is the number of days a patient is admitted to the hospital associated with ICD implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>48 months</time_frame>
    <description>Fluoroscopy time is the total time that fluoroscopy is used during the implantation of either the transvenous ICD or subcutaneous ICD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac (pre-)syncope events</measure>
    <time_frame>48 months</time_frame>
    <description>Cardiac syncope is a loss of consciousness due to cerebral hypoperfusion caused by cardiac arrhythmias or presumed cardiac arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-overs to the other arm</measure>
    <time_frame>48 months</time_frame>
    <description>A crossover to the other arm is defined as a patient who for any reason after randomization is switched to the other ICD arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac decompensation</measure>
    <time_frame>48 months</time_frame>
    <description>Cardiac decompensation refers to acute failure of the heart to maintain adequate blood circulation for which hospitalization and medical treatment is necessary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Ventricular Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Subcutaneous ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous Implantable Cardioverter Defibrillator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transvenous ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transvenous Implantable Cardioverter Defibrillator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of subcutaneous ICD</intervention_name>
    <description>Implantation of subcutaneous ICD</description>
    <arm_group_label>Subcutaneous ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of transvenous ICD</intervention_name>
    <description>Implantation of transvenous ICD</description>
    <arm_group_label>Transvenous ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years and older

          -  Patients with class I or IIa indication for ICD therapy according to the ACC/AHA/ESC
             2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the
             Prevention of Sudden Cardiac Death

        Exclusion Criteria:

          -  Patients with documented therapy refractory monomorphic ventricular tachycardia

          -  Patients having an indication for pacing therapy

          -  Patients with ventricular tachycardia less than 170 bpm

          -  Patients failing appropriate QRS/T-wave sensing with the S-ICD ECG patient screening
             tool provided by Cameron Health/Boston Scientific

          -  Patients with incessant ventricular tachycardia

          -  Patients with a serious known concomitant disease with a life expectancy of less than
             one year

          -  Patients with circumstances that prevent follow-up (no permanent home or address,
             transient, etc.)

          -  Patients who have had a previous ICD implant

          -  Patient who receive cardiac contractility modulation therapy or are likely to receive
             cardiac contractility modulation therapy.

          -  Patients who are unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinoud E Knops, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center - University of Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur A.M. Wilde, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academic Medical Center - University of Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount SinaÏ Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noordwest Hospital</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center - University of Amsterdam (AMC-UvA)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinikum Zwolle</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart &amp; Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georges Hospital of London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, Delnoy PP, van Dessel PF, Driessen AH, de Groot JR, Herrman JP, Jordaens LJ, Kooiman KM, Maass AH, Meine M, Mizusawa Y, Molhoek SG, van Opstal J, Tijssen JG, Wilde AA. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012 May;163(5):753-760.e2. doi: 10.1016/j.ahj.2012.02.012.</citation>
    <PMID>22607851</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>R.E. Knops</investigator_full_name>
    <investigator_title>Drs. R.E. Knops</investigator_title>
  </responsible_party>
  <keyword>Heart rhythm disturbances</keyword>
  <keyword>Implantable cardiac defibrillator</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

